
zzso agents are significantly active in breast cancer cells, but their usefulness has been limited in treating zzso breast cancer zzso This has facilitated the development of an approach using zzso zzso zzso zzso including zzso A, zzso B, human zzso growth factor zzso type 2 zzso zzso and zzso tumors exhibit original drug responsiveness and clinical zzso zzso treatments, zzso or zzso have demonstrated clinically significant zzso Poly zzso zzso zzso act against zzso breast zzso Cancer stem cells could be the major obstacle to achieving a cure in systemic zzso zzso investigations are zzso to develop novel agents that act on the genes or signaling of zzso zzso and zzso which regulate cancer stem zzso Cancer cells undergo zzso transition zzso and acquire invasive zzso Breast cancer cells alter their zzso in blood and bone zzso zzso circulating tumor cells or zzso tumor zzso Cancer stem cells, like normal stem cells, may exist at niches in bone zzso To achieve a cure for zzso it is necessary to disrupt cancer stem zzso interactions or eradicate cancer stem zzso Traditional treatments with zzso or zzso agents require development in relation to intrinsic zzso stem cells, or zzso 

